Sandoz Collaborates with Civica Rx to Help Reduce Critical Generic Medicine Shortages in US Hospitals

Sandoz Inc. today announced it has entered into a long-term agreement with Civica Rx (Civica, Inc.) to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient care. Under the five-year agreement, Sandoz will supply six injectable medicines widely used at Civica’s 1,200...

Kaiser Permanente Joins Forces with Civica Rx to Improve Availability and Affordability of Essential Generic Medication

Kaiser Permanente, the nation’s largest nonprofit, integrated health system, announced that it is joining with nonprofit Civica Rx in its mission of assuring that health providers nationally have access to stable and affordable supplies of essential generic medications throughout the COVID-19 pandemic and beyond. Kaiser Permanente joins Civica as a governing member with a...

Civica Update: Civica Rx Partners on COVID-19 Response and “End-to-End” U.S. Based Generic Drug Manufacturing

  Civica Rx  is part of a new U.S. Government-funded partnership that was announced today to produce essential generic medicines and their ingredients at one location in the United States. Teams within the Department of Health and Human Services (HHS) are working with a team of private industry partners to expand generic pharmaceutical manufacturing...

Recent Recognition

Fast Company lists Civica as one of The World's 50 Most Innovative Companies for manufacturing generic drugs at lower prices to combat shortages and rising healthcare costs. Modern Healthcare names Martin VanTrieste, President and CEO of Civica Rx, as one of The 100 Most Influential People in Healthcare. “This recognition is a reflection of everything the...

Civica Rx ANDA Statement

Civica Rx today announced that it is interested in talking to generic drug manufacturers who are considering retiring or withdrawing their Abbreviated New Drug Applications (ANDAs) for essential medicines that are at risk of being in short supply. Periodically, the FDA withdraws approvals of ANDAs due to manufacturer inactivity. According to published reports, the...

Scroll to top